Investigation of the effectiveness of oral lorazepam in managing preoperative dental anxiety in phobic dental patients-A pilot study - Oral lorazepam for managing dental anxiety.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-003749-15-GB

Enrollment

Registered

2005-10-14

Start date

2006-02-02

Completion date

Unknown

Last updated

2012-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre operative dental anxiety, in phobic dental patients.

Interventions

Product Name: Lorazepam 500 mirograms Capsules Pharmaceutical Form: Capsule, hard INN or Proposed INN: Lorazepam CAS Number: 846-49-1 Concentration unit: µg microgram(s) Concentration type: equal Conc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients referred to the sedation department due to disproportionate dental anxiety Score 15+ on a Corah dental Anxiety scale ASA 1&2 Aged 18-50 Able to: attend Newcastle Dental Hospital for treatment; understand the trial; give written consent;take the medication twice daily, in divided doses; avoid driving/working/drinking for the 3 day trial period Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Refusal to participate Corah score <15 Inability to understand the consent/questionnaires Inability to attend within the time of the trial Unable to take the medication Unable to restrain from driving/drinking for the 3 days of the trial.

Design outcomes

Primary

Measure	Time frame
Main Objective: This pilot study aims to determine the feasibility and the effective dose of oral lorazepam in managing pre operative anxiety in phobic dental patients, scheduled to undergo dental treatment under conscious sedation. ;Secondary Objective: None;Primary end point(s):	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026